Breathe Easier: The Future of COPD and Asthma Management is Here!
"Discover how near-patient testing is revolutionizing the way we monitor and manage COPD and asthma, offering faster results and better care."
In today's fast-paced world, quick and accurate medical decisions are more important than ever. For individuals battling chronic respiratory diseases like Chronic Obstructive Pulmonary Disease (COPD) and asthma, timely diagnosis and treatment can significantly improve their quality of life. Traditional lab testing methods often involve long waiting periods, which can delay crucial treatment decisions. However, a new approach known as near-patient testing (NPT) is emerging as a game-changer in respiratory care.
Near-patient testing offers the promise of rapid results, enabling healthcare providers to make informed decisions right at the point of care. This not only saves time but can also lead to more effective management of these chronic conditions. In the context of COPD, for instance, the peripheral blood eosinophil count has proven valuable in predicting treatment response and providing essential prognostic information during acute exacerbations. Imagine having a reliable NPT method to quickly assess eosinophil levels – it could revolutionize how we approach COPD and asthma management.
This article explores the potential of NPT, specifically focusing on the HemoCue® WBC Diff System, as a reliable and efficient tool for measuring blood eosinophil counts. We delve into a study that compares this NPT method with standard laboratory analysis in healthy, asthmatic, and COPD subjects, highlighting its accuracy and potential to transform the speed and effectiveness of airway disease treatment.
Measuring Respiratory Impact
Asthma surveillance encompasses prevalence, activity limitation, lost work or school days, rescue and control medication use, self-management education, physician visits, emergency department visits, hospitalizations, and deaths. The CDC reports that data for these measures come from National Center for Health Statistics surveys and the Vital Statistics system. Data from 31 U.S. states also indicate that more than one-third of working adults with current asthma have COPD, while asthma-COPD overlap prevalence reached 52% among workers with work-related asthma. These measures illustrate why respiratory disease requires both population-level monitoring and careful attention to overlapping conditions.
From Symptoms to Biomarkers
The history of COPD spans roughly 200 years and includes the evolving understanding of emphysema, chronic bronchitis, and asthmatic bronchitis. The stethoscope and spirometer became important early tools in that development. More recent diagnostic guidance incorporates biomarkers: NICE recommends measuring blood eosinophils or fractional exhaled nitric oxide, and states that asthma can be diagnosed when eosinophils exceed the laboratory reference range or FeNO is 50 ppb or more. Research on early-life origins also reports that much of the lung-function reduction seen at age 50 in people with COPD and a history of severe childhood asthma was already established during childhood.
What is Near-Patient Testing and Why Does It Matter?
Near-patient testing (NPT) is a diagnostic approach that brings testing directly to the patient's location, whether it's a clinic, bedside, or even their home. Unlike traditional lab testing, which requires sending samples to a centralized laboratory and waiting for results, NPT devices provide rapid, on-the-spot analysis. This speed is particularly crucial in managing chronic conditions like COPD and asthma, where timely interventions can significantly impact patient outcomes.
- Faster Results: NPT provides results within minutes, allowing for quicker treatment decisions.
- Improved Convenience: Testing can be performed at the point of care, reducing the need for lab visits.
- Cost-Effectiveness: NPT can reduce the overall cost of healthcare by minimizing delays and optimizing treatment strategies.
- Better Patient Outcomes: Timely interventions based on rapid results can lead to improved management of chronic conditions.
Refining COPD Management
The 2025 GOLD Report introduces three new figures that reflect updated approaches to COPD care. These include pre- and post-bronchodilator spirometry, management of patients currently receiving LABA plus inhaled corticosteroids, and treatable traits in pulmonary hypertension-COPD with suggested management. The additions show how contemporary reviews are expanding beyond a single treatment pathway toward more detailed assessment of lung function, medication strategy, and clinically relevant traits.
Limits of One-Size-Fits-All Care
Evidence in asthma-COPD overlap highlights important limits and uncertainties in treatment. A retrospective cohort of 8,045 people reported that those who smoked cigarettes throughout the 25-year observation period had a higher risk of COPD than nonsmokers, 36% versus 8%. In COPD, inhaled corticosteroids have been associated with increased FEV1 and reduced lung-function decline, but inhaled-corticosteroid monotherapy is not recommended because its risk-benefit balance compared with ICS/LABA therapy remains unclear in relation to pneumonia. The STARR2 trial also had to convert from a superiority design to a non-inferiority analysis after an error in its randomization code was identified before data lock, while the American Thoracic Society issued only a conditional recommendation for FeNO-guided asthma care because the overall evidence quality was low.
Different Diseases, Different Strategies
Asthma and COPD can produce similar symptoms, but the Cleveland Clinic emphasizes that their treatment strategies differ and that accurate diagnosis is essential. Asthma management often uses inhaled corticosteroids as the primary treatment, with bronchodilators added or used for acute relief. COPD treatment more commonly begins with long-acting bronchodilators such as salmeterol or tiotropium, with inhaled corticosteroids added in selected cases. The NHLBI also reports that more than 16 million Americans have been diagnosed with COPD, while millions more have the disease without knowing it.
The Future of Respiratory Care
The integration of near-patient testing into routine clinical practice holds significant promise for improving the management of COPD and asthma. By providing rapid and reliable measurements of key biomarkers like eosinophil counts, NPT enables healthcare providers to make more informed treatment decisions, leading to better patient outcomes and a more efficient healthcare system. As technology advances, we can expect even more innovative NPT solutions to emerge, further transforming the landscape of respiratory care.
Toward Smarter Respiratory Care
Emerging respiratory care is being described in terms of biologic medications, smart inhalers, wearable respiratory monitoring, AI-assisted diagnostics, and regenerative lung research. These approaches aim to improve disease control, early detection, medication personalization, and long-term respiratory health. One market analysis estimates that the global asthma and COPD drugs market was worth about USD 40.3 billion in 2024 and could reach about USD 86.36 billion by 2034, representing a projected CAGR of 7.92% from 2025 to 2034. The same analysis identifies AI-supported use of clinical, genomic, and proteomic data as part of efforts to develop personalized treatment plans.
Integrated Care for Overlapping Conditions
Managing asthma and COPD is described as a multifaceted challenge requiring coordination across healthcare disciplines. Recent work calls for integrated strategies that address both conditions while reducing treatment-related side effects, particularly as inhaled corticosteroids are used for asthma and for selected COPD patients with eosinophilic inflammation or repeated exacerbations. A proposed Asthma-COPD-OSA Outpatient Unit would integrate systematic screening, diagnosis, treatment initiation, and long-term follow-up for obstructive sleep apnea in patients with asthma and COPD. Diagnostic frameworks also remain distinct: GINA provides guidance for asthma, while GOLD provides an evidence-based strategy for COPD diagnosis and treatment.